VTRS Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals has a net margin of -14.64% compared to Viatris's net margin of -5.39%. Viatris's return on equity of -3.22% beat ANI Pharmaceuticals's return on equity of -4.07%.

Viatris has a consensus price target of $12.5125, signalling upside risk potential of 33.82%. On the other hand ANI Pharmaceuticals has an analysts' consensus of $80.83 which suggests that it could grow by 38.25%. Given that ANI Pharmaceuticals has higher upside potential than Viatris, analysts believe ANI Pharmaceuticals is more attractive than Viatris.

Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison ANI Pharmaceuticals has a beta of 0.625, suggesting its less volatile than the S&P 500 by 37.453%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.13%. ANI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. ANI Pharmaceuticals pays out -8.77% of its earnings as a dividend.

Viatris quarterly revenues are $3.5B, which are larger than ANI Pharmaceuticals quarterly revenues of $190.6M. Viatris's net income of -$516.5M is lower than ANI Pharmaceuticals's net income of -$10.3M. Notably, Viatris's price-to-earnings ratio is -- while ANI Pharmaceuticals's PE ratio is 55.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 1.85x for ANI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of -14.64% compared to Viatris's net margin of 12.41%. Viatris's return on equity of -3.22% beat Boston Scientific's return on equity of 8.96%.

Viatris has a consensus price target of $12.5125, signalling upside risk potential of 33.82%. On the other hand Boston Scientific has an analysts' consensus of $115.01 which suggests that it could grow by 9.67%. Given that Viatris has higher upside potential than Boston Scientific, analysts believe Viatris is more attractive than Boston Scientific.

Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.13%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.5B, which are smaller than Boston Scientific quarterly revenues of $4.6B. Viatris's net income of -$516.5M is lower than Boston Scientific's net income of $566M. Notably, Viatris's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 83.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 9.31x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics has a net margin of -14.64% compared to Viatris's net margin of -106.6%. Viatris's return on equity of -3.22% beat Iovance Biotherapeutics's return on equity of -52.91%.

Viatris has a consensus price target of $12.5125, signalling upside risk potential of 33.82%. On the other hand Iovance Biotherapeutics has an analysts' consensus of $19.62 which suggests that it could grow by 387.34%. Given that Iovance Biotherapeutics has higher upside potential than Viatris, analysts believe Iovance Biotherapeutics is more attractive than Viatris.

Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison Iovance Biotherapeutics has a beta of 0.931, suggesting its less volatile than the S&P 500 by 6.856%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.13%. Iovance Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Iovance Biotherapeutics pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.5B, which are larger than Iovance Biotherapeutics quarterly revenues of $73.7M. Viatris's net income of -$516.5M is lower than Iovance Biotherapeutics's net income of -$78.6M. Notably, Viatris's price-to-earnings ratio is -- while Iovance Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 7.11x for Iovance Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -14.64% compared to Viatris's net margin of 16.85%. Viatris's return on equity of -3.22% beat Insulet's return on equity of 43.11%.

Viatris has a consensus price target of $12.5125, signalling upside risk potential of 33.82%. On the other hand Insulet has an analysts' consensus of $312.88 which suggests that it could grow by 14.76%. Given that Viatris has higher upside potential than Insulet, analysts believe Viatris is more attractive than Insulet.

Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.13%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.5B, which are larger than Insulet quarterly revenues of $597.5M. Viatris's net income of -$516.5M is lower than Insulet's net income of $100.7M. Notably, Viatris's price-to-earnings ratio is -- while Insulet's PE ratio is 47.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 9.72x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.